VEGFA and hypertensive disorder: Nonetheless, in vivo studies have shown that ACEi increases release of NO and are thus recommended as first line agents for management of anti-VEGF induced hypertension [11]; especially for their renoprotective effects given higher risk of proteinuria on VSP inhibition therapy [12].